CASTLEFORD, England, March 12, 2012 /PRNewswire/ --
We are pleased to announce the day one launch of generic Naratriptan film-coated tablets. This is the second product launched this month for migraine sufferers.
Naratriptan is a generic version of Naramig® (Naratriptan Hydrochloride) from GlaxoSmithKline UK. It is indicated in the acute treatment of the headache phase of migraine attacks with or without aura.
Naratriptan is available immediately in Teva's award-winning 360 livery. Key product information is as follows:
Teva Brand retail Product Strength Pack Size Indication price price Acute treatment of the headache phase of 2.5mg migraine attacks with Naratriptan film-coated 6 or without aura GBP24.45 GBP6.14 Acute treatment of the headache phase of 2.5mg migraine attacks with Naratriptan film-coated 12 or without aura GBP49.10 GBP12.28
Kim Innes, Commercial Director said: "We want to make more medicines accessible for more people and Naratriptan is our fifth day-one launch this year to add to our portfolio of over 700 products. It's good for Pharmacy because patent expiries provide opportunities for increasing margins and keeping costs down. Importantly, it also means we continue to help save the NHS over £9bn on generic prescriptions."
Teva products are available through local Territory Managers, major wholesalers or contact 0800-085-8621.
Notes to Editors:
About Teva UK Limited
Teva UK Limited is one of the UK's top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd.
About Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 47,000 people around the world and reached $16.1 billion in net sales in 2010.
For media enquiries, contact the Teva UK Limited Media team on +44(0)1977-628500, or email firstname.lastname@example.org.
SOURCE Teva UK Ltd